The offering follows positive clinical data, suggesting confidence in the pipeline. The substantial capital raise combined with strong cash position provides runway for multiple clinical programs. Traders should monitor enrollment in Part B of the SKYLINE trial and upcoming data readouts for SPY002 and SPY003.
Price Chart
Executive Summary
Spyre Therapeutics is raising $300 million through a common stock offering, following positive Phase 2 topline data for its lead candidate SPY001 in ulcerative colitis. The company reported preliminary cash of $741 million as of March 31, 2026, and has terminated its prior ATM offering. The capital will fund ongoing clinical programs in inflammatory bowel and rheumatic diseases.
Key Facts
- Spyre Therapeutics is offering $300 million of common stock
- Positive Phase 2 topline data for SPY001 in ulcerative colitis showed statistically significant reduction in RHI score of 9.2 points (p<0.0001)
- Company reported preliminary cash of $741 million as of March 31, 2026
- Terminated prior ATM offering in connection with this new offering
- Proceeds will fund clinical programs in IBD and rheumatic diseases
- Stock priced at $51.29 per share on April 10, 2026, prior to announcement
Financial Impact
Raises $300 million in gross proceeds, with net proceeds to be used for advancing clinical programs. Company had $741 million in cash as of March 31, 2026.
Risk Factors
- Dilution to existing shareholders from the $300 million offering
- Clinical trial risks for ongoing and future studies
- Competition in the IBD and rheumatic disease markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001628280-26-024940 |
| Document: 0001628280-26-024940-index-headers.html | 0001628280-26-024940 |
| Document: 0001628280-26-024940-index.html | 0001628280-26-024940 |
| Document: 0001628280-26-024940.txt | 0001628280-26-024940 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | Insider Cluster | $88.98 $90.80 | ▼ −2.05% | ▼ −3.25% | $93.19 (−4.73%) |
Aug 11, 2026 7w ago | Insider Cluster | $102.74 $107.82 | ▼ −4.94% | ▼ −5.35% | $93.19 (+9.30%) |
Aug 6, 2026 8w ago | Insider Cluster | $103.42 $101.85 | ▲ +1.52% | ▲ +2.73% | $93.19 (+9.89%) |
Jul 3, 2026 13w ago | Insider Cluster | $86.63 $98.75 | ▲ +13.99% | ▲ +13.06% | $93.19 (+7.57%) |
Jun 27, 2026 13w ago | Insider Cluster | $90.16 $88.74 | ▲ +1.57% | ▲ +2.96% | $93.19 (−3.36%) |
Jun 26, 2026 14w ago | S-3ASR | $90.16 $88.74 | ▼ −1.57% | ▼ −2.96% | $93.19 (+3.36%) |
Jun 24, 2026 14w ago | Insider Cluster | $86.24 $88.89 | ▼ −3.07% | ▼ −1.37% | $93.19 (−8.06%) |
Jun 15, 2026 15w ago | 8-K | $83.58 $100.32 | ▲ +20.03% | ▲ +21.41% | $93.19 (+11.50%) |
Jun 12, 2026 16w ago | Institutional Cluster | $80.79 $88.34 | ▲ +9.35% | ▲ +8.67% | $93.19 (+15.35%) |
Jun 11, 2026 16w ago | Institutional Cluster | $80.77 $87.49 | ▲ +8.32% | ▲ +7.89% | $93.19 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access